Akero Therapeutics (NASDAQ:AKRO) Research Coverage Started at Evercore ISI

Share on StockTwits

Research analysts at Evercore ISI started coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a report issued on Monday, Marketbeat reports. The brokerage set an “outperform” rating and a $35.00 price target on the stock. Evercore ISI’s price target would suggest a potential upside of 70.48% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. restated a “sell” rating and set a $18.00 price objective on shares of ABB in a research report on Monday. Roth Capital restated a “buy” rating on shares of Coeur Mining in a research report on Monday. Finally, Jefferies Financial Group lowered their price objective on shares of TherapeuticsMD from $4.00 to $3.00 in a research report on Monday.

Shares of Akero Therapeutics stock opened at $20.53 on Monday. Akero Therapeutics has a twelve month low of $16.06 and a twelve month high of $21.94.

In other Akero Therapeutics news, Director Seth Loring Harrison purchased 900,000 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $14,400,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Global Strategic Fund I. Venbio purchased 250,000 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $4,000,000.00. The disclosure for this purchase can be found here.

About Akero Therapeutics

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Recommended Story: Equity Income

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
7,019 Shares in D. R. Horton Inc  Bought by Wedbush Securities Inc.
7,019 Shares in D. R. Horton Inc Bought by Wedbush Securities Inc.
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust


© 2006-2019 Ticker Report